Download Files:

3-Deazaneplanocin A (hydrochloride) (GMP)

Products Details

Product Description

– 3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor[1][2].

Web ID

– HY-12186G

Shipping

– Room temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C12H15ClN4O3

References

– [1]Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009 Sep 24;114(13):2733-43. |[2]Hou P, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013 Aug 9;341(6146):651-4. |[3]Zhao C, et al. DZNep and UNC0642 enhance in vitro developmental competence of cloned pig embryos. Reproduction. 2018 Apr 1;157(4):359-369.

CAS Number

– 120964-45-6

Molecular Weight

– 298.73

SMILES

– O[C@@H]1[C@H](O)C(CO)=C[C@H]1N2C=NC3=C2C=CN=C3N.[H]Cl

Clinical Information

– No Development Reported

Research Area

– Cancer; Infection

Solubility

– 10 mM in DMSO

Target

– Histone Methyltransferase;Orthopoxvirus

Isoform

– EZH2

Pathway

– Anti-infection;Epigenetics

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.